Dai ichi Life Insurance Company Ltd Sells 16,741 Shares of Insulet Corporation $PODD

Dai ichi Life Insurance Company Ltd trimmed its holdings in Insulet Corporation (NASDAQ:PODD) by 87.2% in the first quarter, Holdings Channel reports. The institutional investor owned 2,468 shares of the medical instruments supplier’s stock after selling 16,741 shares during the quarter. Dai ichi Life Insurance Company Ltd’s holdings in Insulet were worth $518,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Renaissance Technologies LLC boosted its holdings in shares of Insulet by 40.5% in the first quarter. Renaissance Technologies LLC now owns 426,003 shares of the medical instruments supplier’s stock worth $89,392,000 after acquiring an additional 122,720 shares during the period. Arrowstreet Capital Limited Partnership raised its stake in shares of Insulet by 462.7% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 1,229,928 shares of the medical instruments supplier’s stock valued at $258,088,000 after purchasing an additional 1,011,369 shares during the period. Caxton Associates LLP purchased a new stake in Insulet during the 1st quarter worth about $290,000. Gibbs Wealth Management lifted its holdings in Insulet by 205.0% during the 1st quarter. Gibbs Wealth Management now owns 2,196 shares of the medical instruments supplier’s stock worth $461,000 after purchasing an additional 1,476 shares in the last quarter. Finally, Walleye Capital LLC boosted its stake in Insulet by 318.4% in the 1st quarter. Walleye Capital LLC now owns 4,886 shares of the medical instruments supplier’s stock worth $1,025,000 after purchasing an additional 7,123 shares during the period.

Insulet Price Performance

Insulet stock opened at $165.00 on Tuesday. The stock has a market cap of $11.43 billion, a price-to-earnings ratio of 38.37, a PEG ratio of 1.14 and a beta of 1.11. The company has a quick ratio of 1.81, a current ratio of 2.49 and a debt-to-equity ratio of 0.71. The business has a 50-day simple moving average of $154.34 and a 200 day simple moving average of $201.13. Insulet Corporation has a 52 week low of $138.79 and a 52 week high of $354.88.

Insulet (NASDAQ:PODD) last released its quarterly earnings results on Wednesday, May 6th. The medical instruments supplier reported $1.42 earnings per share for the quarter, beating the consensus estimate of $1.19 by $0.23. The firm had revenue of $761.70 million for the quarter, compared to analysts’ expectations of $729.89 million. Insulet had a return on equity of 26.87% and a net margin of 10.44%.The company’s revenue was up 33.9% compared to the same quarter last year. During the same quarter last year, the firm posted $1.02 EPS. Insulet has set its FY 2026 guidance at 6.210- EPS. On average, research analysts forecast that Insulet Corporation will post 6.45 earnings per share for the current fiscal year.

Insider Buying and Selling at Insulet

In related news, Director Timothy C. Stonesifer acquired 2,790 shares of the firm’s stock in a transaction that occurred on Wednesday, June 3rd. The shares were bought at an average cost of $143.51 per share, for a total transaction of $400,392.90. Following the completion of the transaction, the director owned 9,041 shares in the company, valued at approximately $1,297,473.91. This trade represents a 44.63% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 0.36% of the company’s stock.

Analyst Ratings Changes

PODD has been the subject of a number of recent analyst reports. Benchmark reaffirmed a “buy” rating on shares of Insulet in a report on Wednesday, May 27th. Evercore set a $180.00 price objective on shares of Insulet in a research report on Monday, July 6th. Robert W. Baird reduced their price objective on shares of Insulet from $360.00 to $248.00 in a research note on Thursday, May 7th. Raymond James Financial set a $216.00 price objective on shares of Insulet in a research note on Monday, June 8th. Finally, The Goldman Sachs Group reaffirmed a “buy” rating and set a $205.00 target price on shares of Insulet in a report on Wednesday, May 27th. Twenty-two analysts have rated the stock with a Buy rating, four have issued a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $235.25.

Insulet News Roundup

Here are the key news stories impacting Insulet this week:

• Neutral Sentiment: Multiple firms—including Rosen, Bronstein Gewirtz & Grossman, Levi & Korsinsky, Faruqi & Faruqi, and Bleichmar Fonti & Auld—issued substantially similar notices. The repeated releases primarily seek to attract investors to the existing litigation rather than announce separate new legal actions. Rosen investor notice
• Neutral Sentiment: The proposed class periods vary by notice, generally covering purchases from February 21 or May 21, 2025, through May 26, 2026. Investors who purchased during the applicable period may petition the court by August 31, 2026, to serve as lead plaintiff, with firms stating that representation is offered on a contingency-fee basis. Levi and Korsinsky notice
• Negative Sentiment: The lawsuit creates a potential financial liability, management distraction, and ongoing uncertainty for Insulet. Continued legal notices may weigh on investor sentiment, particularly because the allegations relate to conduct that plaintiffs say contributed to the earlier stock selloff. Bleichmar Fonti and Auld lawsuit notice

Insulet Company Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.